Sarah Knerr

Sarah Knerr

Auto-generated profile, based on publicly available information

Sarah Knerr

Department of Health Systems and Population Health, University of Washington School of Public Health

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2014 in Journal of Empirical Research on Human Research Ethics
Verified
Journal Article
Closed access
PDF file
RCRachel M. Ceballos
Rachel M. Ceballos
SKSarah Knerr
Sarah Knerr
MSMary Alice Scott
Mary Alice Scott
SHSarah D. Hohl
Sarah D. Hohl
RMRachel C. Malen
Rachel C. Malen
BTBeti Thompson
Beti Thompson
Latinos are under-represented in biomedical research conducted in the United States, impeding disease prevention and treatment efforts for this growing demographic group. We gathered perceptions of biomedical research and gauged willingness to participate through elicitation interviews and focus groups with Latinos living on the U.S.–Mexico border. Themes that emerged included a strong willingness to participate in biomedical studies and suggested that Latinos may be under-represented due to limited formal education and access to health information, not distrust. The conflation of research and clinical care was common and motivated participation. Outreach efforts and educational interventions to inform Latinos of participation opportunities and clarify harms and benefits associated with biomedical research participation will be essential to maintain trust within Latino communities.

8 February 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SKSarah Knerr
Sarah Knerr
EBErin J A Bowles
Erin J A Bowles
KLKathleen A Leppig
Kathleen A Leppig
DBDiana S M Buist
Diana S M Buist
HGHongyuan Gao
Hongyuan Gao
KWKaren J Wernli
Karen J Wernli
Genetic testing to determine BRCA status has been available for over two decades, but there are few population-based studies of test diffusion. We report 10-year trends in BRCAtesting in an integrated health-care system with long-standing access to genetic services. A cohort of women aged 18 years and older was created to ascertain BRCA testing (n = 295 087). Annual testing rates between 2005 and 2015 were calculated in all women with and without incident (ie, newly diagnosed) breast and ovarian cancers and in clinically eligible subgroups by family cancer history, personal cancer history, and age at diagnosis. Secular trends were assessed using Poisson regression. Women tested early (2005–2008), midway (2009–2012), and late (2013–2015) in the study period were compared in cross-sectional analyses. Between 2005 and 2015, annual testing rates increased from 0.6/1000 person-years (pys) (95% confidence interval [CI] = 0.4 to 0.7/1000 pys) to 0.8/1000 pys (95% CI = 0.6 to 1.0/1000 pys) in women without incident breast or ovarian cancers. Rates decreased from 71.5/1000 pys (95% CI = 42.4 to 120.8/1000 pys) to 44.4/1000 pys (95% CI = 35.5 to 55.6/1000 pys) in women with incident diagnoses, despite improvements in provision of timely BRCA testing during this time frame. We found no evidence of secular trends in clinically eligible subgroups including women with family history indicating increased hereditary cancer risk, but no personal cancer history. At the end of the study period, 97.0% (95% CI = 96.6% to 97.3%) of these women remained untested. Many eligible women did not receive BRCA testing despite having insurance coverage and access to specialty genetic services, underscoring challenges to primary and secondary hereditary cancer prevention.

1 January 2011 in Journal of Law, Medicine & Ethics
Verified
Journal Article
Closed access
SKSarah Knerr
Sarah Knerr
DWDawn Wayman
Dawn Wayman
VBVence L. Bonham
Vence L. Bonham

3 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
KMKathleen F. Mittendorf
Kathleen F. Mittendorf
SKSarah Knerr
Sarah Knerr
TKTia L. Kauffman
Tia L. Kauffman
NLNangel M. Lindberg
Nangel M. Lindberg
KAKatherine P. Anderson
Katherine P. Anderson
KGKatrina A. B. Goddard
Katrina A. B. Goddard

1 March 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
HCHeather H. Cheng
Heather H. Cheng
ASAlexandra O. Sokolova
Alexandra O. Sokolova
RGRoman Gulati
Roman Gulati
DBDeborah Bowen
Deborah Bowen
SKSarah A. Knerr
Sarah A. Knerr
BMBruce Montgomery
Bruce Montgomery
PURPOSE: Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS: In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS: As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION: Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization.

1 April 2012 in Public Health Genomics
Verified
Journal Article
Open access
PDF file
SFStephanie Malia Fullerton
Stephanie Malia Fullerton
SKS. Knerr
S. Knerr
WBW. Burke
W. Burke
The existence of pronounced differences in health outcomes between US populations is a problem of moral significance and public health urgency. Pursuing research on genetic contributors to such disparities, despite striking data on the fundamental role of social factors, has been controversial. Still, advances in genomic science are providing an understanding of disease biology at a level of precision not previously possible. The potential for genomic strategies to help in addressing population-level disparities therefore needs to be carefully evaluated. Using 3 examples from current research, we argue that the best way to maximize the benefits of population-based genomic investigations, and mitigate potential harms, is to direct research away from the identification of genetic causes of disparities and instead focus on applying genomic methodologies to the development of clinical and public health tools with the potential to ameliorate healthcare inequities, direct population-level health interventions or inform public policy. Such a transformation will require close collaboration between transdisciplinary teams and community members as well as a reorientation of current research objectives to better align genomic discovery efforts with public health priorities and well-recognized barriers to fair health care delivery.